Improvement in Health-Related Quality of Life with Rizatriptan 10mg Compared with Standard Migraine Therapy
作者:William C. Gerth、Kevin H. Ruggles、Stuart R. Stark、Glenn M. Davies、Nancy C. Santanello
DOI:10.2165/00044011-200121120-00008
日期:——
To compare the effects of rizatriptan and patients’ usual migraine medication(s) on health-related quality of life. The study was a non-blinded, parallel-group, extension trial in which patients who had completed a randomised, placebo-controlled trial of the treatment of migraine with rizatriptan at 23 study sites in the United States were randomly assigned in a 4: 1 ratio either to rizatriptan or to standard care. 265 migraineurs, 18 to 65 years of age. Patients received either rizatriptan 10mg or their usual migraine medication(s). The main outcome measures were: (a) migraine-specific quality of life during the 24-hour period of an attack, as determined by the 24-Hour Migraine-Specific Quality-of-Life Questionnaire (24-HrMQoLQ), for attacks in the first month; (b) general health-related quality of life as determined by the eight domain scores and the Mental and Physical Component Scales of the Short Form Health Survey (SF-36) after 2, 6 and 12 months. The 24-HrMQoLQ domains were scored from 3 to 21, and the SF-36 from 0 to 100, higher scores indicating better performance for both instruments. Patients receiving rizatriptan had significantly better scores in all five domains of the 24-HrMQoLQ compared with patients receiving standard care. Mean scores (standard error) for the rizatriptan and usual care groups were, respectively: Work Functioning, 13.9 (0.4), 12.5 (0.8), p = 0.05; Social Functioning, 13.6 (0.4), 11.8 (0.8), p = 0.015; Energy/Vitality, 13.7 (0.5), 11.6 (0.8), p < 0.01; Feelings/Concerns 13.3 (0.4), 10.6 (0.8), p < 0.001; and Migraine Symptoms 14.1 (0.4), 12.1 (0.7), p < 0.01. There was a trend for patients receiving rizatriptan to have higher scores on the Mental Component Scale of the SF-36: mean score (SE) 50.3 (0.6) for rizatriptan, 48.0 (1.1) for usual care, p = 0.068. There was no difference between the treatment groups in the Physical Component Scale: mean score (SE) 48.4 (0.6) for rizatriptan, 49.7 (1.1) for usual care, p = 0.202. Quality of life in the 24-hour period following a migraine attack was better in patients treated with rizatriptan 10mg than in patients treated with their usual migraine medication.
比较利扎曲普坦和患者常用偏头痛药物对健康相关生活质量的影响。该研究是一项非盲、平行组、扩展试验,在美国的23个研究地点完成了使用利扎曲普坦治疗偏头痛的随机、安慰剂对照试验的患者按照4:1的比例被随机分配到利扎曲普坦或标准护理中。265名偏头痛患者,年龄在18至65岁之间。患者接受利扎曲普坦 10 毫克或其惯用的偏头痛药物治疗。主要结果指标为(a) 24 小时偏头痛生活质量调查表(24-HrMQoLQ)显示的偏头痛发作 24 小时内的生活质量(第一个月的发作情况);(b) 2 个月、6 个月和 12 个月后的一般健康相关生活质量(通过短式健康调查表(SF-36)的 8 个领域得分以及精神和身体成分量表来确定)。24-HrMQoLQ领域的评分范围为3-21分,SF-36的评分范围为0-100分,得分越高表明两种工具的效果越好。与接受标准治疗的患者相比,接受利扎曲普坦治疗的患者在24-HrMQoLQ的所有五个领域中的得分都明显更高。利扎曲普坦组和常规护理组的平均得分(标准误差)分别为工作功能,13.9 (0.4),12.5 (0.8),p = 0.05;社交功能,13.6 (0.4),11.8 (0.8),p = 0.015;精力/活力,13.7 (0.5),11.6 (0.8),p = 0.015;精力/活力,13.7 (0.5),11.8 (0.8),p = 0.015;感觉/忧虑,13.3 (0.4),10.6 (0.8),p = 0.001;偏头痛症状,14.1 (0.4),12.1 (0.7),p = 0.01。接受利扎曲普坦治疗的患者在SF-36心理成分量表上的得分有上升趋势:利扎曲普坦治疗组的平均得分(SE)为50.3(0.6),常规治疗组为48.0(1.1),P = 0.068。在体能成分量表方面,治疗组之间没有差异:利扎曲普坦的平均得分(SE)为 48.4(0.6),常规护理为 49.7(1.1),P = 0.202。在偏头痛发作后的24小时内,接受利扎曲普坦10毫克治疗的患者的生活质量优于接受常规偏头痛药物治疗的患者。